Loading…

Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans

A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weigh...

Full description

Saved in:
Bibliographic Details
Published in:DRUG METABOLISM AND PHARMACOKINETICS 2010-01, Vol.25 (4), p.367-378
Main Authors: Kato, Motohiro, Chiba, Koji, Ito, Takashi, Koue, Toshiko, Sugiyama, Yuichi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913
cites cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913
container_end_page 378
container_issue 4
container_start_page 367
container_title DRUG METABOLISM AND PHARMACOKINETICS
container_volume 25
creator Kato, Motohiro
Chiba, Koji
Ito, Takashi
Koue, Toshiko
Sugiyama, Yuichi
description A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.
doi_str_mv 10.2133/dmpk.DMPK-09-RG-038
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754013016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1347436715300446</els_id><sourcerecordid>754013016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</originalsourceid><addsrcrecordid>eNp9kE1PFTEUhidGI4j-AhMzO1eD_Zz2LlyQi1yIGG9QSFyYph9nYmGmvbYdEv69nVxg6aanad_znPZpmvcYHRNM6Sc37e6OT79tv3Zo1V1tOkTli-YQS4nqAUEv654y0THai4PmTc63CFHKGXndHBAkMcNcHja_twmct8XH0MahvQgFkg_O33s367G90clr40dfHlof2u0fnSZt450PULzN7RBTu_61pSes_TGbXJIukJfk-TzpkN82rwY9Znj3WI-a67MvP9fn3eX3zcX65LKzPSalYxyDIBIRbKzQxnFsJV85wxBzuGcgsASNBwuaGGNJT6hm1CDobb2jK0yPmo977i7FvzPkoiafLYyjDhDnrARnCFOE-5qk-6RNMecEg9olP-n0oDBSi1a1aFWLVoVW6mqjqtba9eGRP5sJ3HPPk8caONsHpsWmHmMYqyJ1G-cU6seVjXiCok3tqHMQIhyxWmSl96IuQnIhBacV9HkPgqrr3kNS2XoItmIT2KJc9P996T-SwqDI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754013016</pqid></control><display><type>article</type><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><source>ScienceDirect Freedom Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi</creator><creatorcontrib>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi ; Chugai Pharmaceutical Co ; The University of Tokyo ; Otsuka Pharmaceutical Co ; Daiichi Sankyo Co ; Ltd ; Keio University</creatorcontrib><description>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</description><identifier>ISSN: 1347-4367</identifier><identifier>EISSN: 1880-0920</identifier><identifier>DOI: 10.2133/dmpk.DMPK-09-RG-038</identifier><identifier>PMID: 20814158</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Area Under Curve ; CYP3A4 ; Cytochrome P-450 CYP3A - physiology ; drug discovery ; Humans ; Interindividual variability ; Intestinal Mucosa - metabolism ; Liver - metabolism ; Metabolic Clearance Rate ; Midazolam - pharmacokinetics ; Monte Carlo Method ; Monte Carlo simulation ; Pharmacokinetics ; physiologically based pharmacokinetics ; prediction</subject><ispartof>DRUG METABOLISM AND PHARMACOKINETICS, 2010-01, Vol.25 (4), p.367-378</ispartof><rights>2010 The Japanese Society for the Study of Xenobiotics</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</citedby><cites>FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20814158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kato, Motohiro</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Ito, Takashi</creatorcontrib><creatorcontrib>Koue, Toshiko</creatorcontrib><creatorcontrib>Sugiyama, Yuichi</creatorcontrib><creatorcontrib>Chugai Pharmaceutical Co</creatorcontrib><creatorcontrib>The University of Tokyo</creatorcontrib><creatorcontrib>Otsuka Pharmaceutical Co</creatorcontrib><creatorcontrib>Daiichi Sankyo Co</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><creatorcontrib>Keio University</creatorcontrib><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><title>DRUG METABOLISM AND PHARMACOKINETICS</title><addtitle>Drug Metab Pharmacokinet</addtitle><description>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</description><subject>Area Under Curve</subject><subject>CYP3A4</subject><subject>Cytochrome P-450 CYP3A - physiology</subject><subject>drug discovery</subject><subject>Humans</subject><subject>Interindividual variability</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Liver - metabolism</subject><subject>Metabolic Clearance Rate</subject><subject>Midazolam - pharmacokinetics</subject><subject>Monte Carlo Method</subject><subject>Monte Carlo simulation</subject><subject>Pharmacokinetics</subject><subject>physiologically based pharmacokinetics</subject><subject>prediction</subject><issn>1347-4367</issn><issn>1880-0920</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PFTEUhidGI4j-AhMzO1eD_Zz2LlyQi1yIGG9QSFyYph9nYmGmvbYdEv69nVxg6aanad_znPZpmvcYHRNM6Sc37e6OT79tv3Zo1V1tOkTli-YQS4nqAUEv654y0THai4PmTc63CFHKGXndHBAkMcNcHja_twmct8XH0MahvQgFkg_O33s367G90clr40dfHlof2u0fnSZt450PULzN7RBTu_61pSes_TGbXJIukJfk-TzpkN82rwY9Znj3WI-a67MvP9fn3eX3zcX65LKzPSalYxyDIBIRbKzQxnFsJV85wxBzuGcgsASNBwuaGGNJT6hm1CDobb2jK0yPmo977i7FvzPkoiafLYyjDhDnrARnCFOE-5qk-6RNMecEg9olP-n0oDBSi1a1aFWLVoVW6mqjqtba9eGRP5sJ3HPPk8caONsHpsWmHmMYqyJ1G-cU6seVjXiCok3tqHMQIhyxWmSl96IuQnIhBacV9HkPgqrr3kNS2XoItmIT2KJc9P996T-SwqDI</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Kato, Motohiro</creator><creator>Chiba, Koji</creator><creator>Ito, Takashi</creator><creator>Koue, Toshiko</creator><creator>Sugiyama, Yuichi</creator><general>Elsevier Ltd</general><general>Japanese Society for the Study of Xenobiotics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</title><author>Kato, Motohiro ; Chiba, Koji ; Ito, Takashi ; Koue, Toshiko ; Sugiyama, Yuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Area Under Curve</topic><topic>CYP3A4</topic><topic>Cytochrome P-450 CYP3A - physiology</topic><topic>drug discovery</topic><topic>Humans</topic><topic>Interindividual variability</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Liver - metabolism</topic><topic>Metabolic Clearance Rate</topic><topic>Midazolam - pharmacokinetics</topic><topic>Monte Carlo Method</topic><topic>Monte Carlo simulation</topic><topic>Pharmacokinetics</topic><topic>physiologically based pharmacokinetics</topic><topic>prediction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kato, Motohiro</creatorcontrib><creatorcontrib>Chiba, Koji</creatorcontrib><creatorcontrib>Ito, Takashi</creatorcontrib><creatorcontrib>Koue, Toshiko</creatorcontrib><creatorcontrib>Sugiyama, Yuichi</creatorcontrib><creatorcontrib>Chugai Pharmaceutical Co</creatorcontrib><creatorcontrib>The University of Tokyo</creatorcontrib><creatorcontrib>Otsuka Pharmaceutical Co</creatorcontrib><creatorcontrib>Daiichi Sankyo Co</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><creatorcontrib>Keio University</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>DRUG METABOLISM AND PHARMACOKINETICS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kato, Motohiro</au><au>Chiba, Koji</au><au>Ito, Takashi</au><au>Koue, Toshiko</au><au>Sugiyama, Yuichi</au><aucorp>Chugai Pharmaceutical Co</aucorp><aucorp>The University of Tokyo</aucorp><aucorp>Otsuka Pharmaceutical Co</aucorp><aucorp>Daiichi Sankyo Co</aucorp><aucorp>Ltd</aucorp><aucorp>Keio University</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans</atitle><jtitle>DRUG METABOLISM AND PHARMACOKINETICS</jtitle><addtitle>Drug Metab Pharmacokinet</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>25</volume><issue>4</issue><spage>367</spage><epage>378</epage><pages>367-378</pages><issn>1347-4367</issn><eissn>1880-0920</eissn><abstract>A method for predicting the interindividual variability of human exposure for CYP3A4 substrates using Monte Carlo simulation was developed based on relevant factors. The coefficient of variation (CV) values for CYP3A4 content in human liver microsomes, hepatic blood flow, liver volume and body weight, and the unbound blood fraction were collected from the published literature. The parallel tube and dispersion models were found to be appropriate mathematical models to describe the pharmacokinetics (PK). Simulation results using 33% as the CV for CYP3A4 content reflected reported CV values of the area under the curve (AUC) for 40 CYP3A4 substrates for both intravenous and oral administration. We also successfully predicted the clearance of midazolam in Japanese and in European American subjects. In all cases, the simulated mean and SD values reflected the reported values. Thus, the interindividual variability of the AUC of CYP3A4 substrates was predictable for both intravenous and oral administration.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20814158</pmid><doi>10.2133/dmpk.DMPK-09-RG-038</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1347-4367
ispartof DRUG METABOLISM AND PHARMACOKINETICS, 2010-01, Vol.25 (4), p.367-378
issn 1347-4367
1880-0920
language eng
recordid cdi_proquest_miscellaneous_754013016
source ScienceDirect Freedom Collection; Free Full-Text Journals in Chemistry
subjects Area Under Curve
CYP3A4
Cytochrome P-450 CYP3A - physiology
drug discovery
Humans
Interindividual variability
Intestinal Mucosa - metabolism
Liver - metabolism
Metabolic Clearance Rate
Midazolam - pharmacokinetics
Monte Carlo Method
Monte Carlo simulation
Pharmacokinetics
physiologically based pharmacokinetics
prediction
title Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A55%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20Interindividual%20Variability%20in%20Pharmacokinetics%20for%20CYP3A4%20Substrates%20in%20Humans&rft.jtitle=DRUG%20METABOLISM%20AND%20PHARMACOKINETICS&rft.au=Kato,%20Motohiro&rft.aucorp=Chugai%20Pharmaceutical%20Co&rft.date=2010-01-01&rft.volume=25&rft.issue=4&rft.spage=367&rft.epage=378&rft.pages=367-378&rft.issn=1347-4367&rft.eissn=1880-0920&rft_id=info:doi/10.2133/dmpk.DMPK-09-RG-038&rft_dat=%3Cproquest_cross%3E754013016%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c612t-451e728021bc7abd51c859db404d164e718ea1fcea2bbc2623a43b0e6c4e73913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=754013016&rft_id=info:pmid/20814158&rfr_iscdi=true